Skip to main content
Top
Published in: Cardiovascular Intervention and Therapeutics 2/2011

01-05-2011 | Original Article

Which DES is the most appropriate for very small target vessels? Experimental study of stent expandable performance with SES, PES, ZES and EES

Authors: Yuki Horita, Masanobu Namura, Masatoshi Ikeda, Taketoshi Tsuchiya, Hidenobu Terai, Ryota Fukuoka, Naoto Tama, Toshimitsu Takagi

Published in: Cardiovascular Intervention and Therapeutics | Issue 2/2011

Login to get access

Abstract

The restenosis rate of coronary stent has significantly decreased by implantation of the drug-eluting stent (DES). We often experienced the DES implantation for very small target vessels. The minimum size of DES in Japan and USA is 2.5 mm-diameter, but there were no reports of the expandability of DESs for the very small target vessels with reference diameter <2.2 mm. We clarify the expandable performance of 2.5 mm-DESs for very small target vessels with reference diameter <2.2 mm in vitro and vivo study. We studied 3 pieces in each kind of DES (Sirolimus-eluting stent; SES, Paclitaxel-eluting stent; PES, Zotarolimus-eluting stent; ZES and Everolimus-eluting stent; EES) in vitro and vivo study of the porcine coronary artery with reference diameter <2.2 mm. By using the delivery balloon, each stent was initially dilated with 3.5 atm. And the pressure of 0.5 atm. was applied until it reached the maximum pressure of 12 atm. The minimum pressure of the full expanded stent balloon was estimated as the minimum expandable pressure. The stent-inner diameter and area on each pressure were measured by IVUS. The average minimum expandable pressure (atm.) in vitro/vivo was 4.7/4.5 in SES, 7.2/6.8 in PES, 4.3/4.5 in ZES and 3.8/3.8 in EES. The inner diameter (mm) in vitro/vivo at minimum expandable pressure was 1.81 ± 0.07/1.84 ± 0.05 in SES, 2.31 ± 0.10/2.13 ± 0.13 in PES, 2.41 ± 0.13/1.98 ± 0.31 in ZES and 2.13 ± 0.11/1.88 ± 0.22 in EES. The stent inner-diameter (mm) of DESs at 8 atm. in vivo was 2.16/2.21/2.45/2.25 in SES/PES/ZES/EES. All kinds of DES could be delivered to very small target vessels with reference diameter <2.2 mm at the minimum expandable pressure in vivo study, but the stent which presented adequate stent inner-diameter at 8 atm. was only SES. We have to implant the 2.5 mm-DESs for very small target vessels according to the data based on this expandability of DESs to bail out threatening occlusion due to coronary dissection or elastic recoil.
Literature
1.
go back to reference Fishman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496–501.CrossRef Fishman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496–501.CrossRef
2.
go back to reference Serrys PW, Jaegere PD, Kiemeneij F, Macaya C, Ritsch W, Heyndrickx G, et al. A comparison of balloon expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489–95.CrossRef Serrys PW, Jaegere PD, Kiemeneij F, Macaya C, Ritsch W, Heyndrickx G, et al. A comparison of balloon expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489–95.CrossRef
3.
go back to reference George CL, Baim DS, Brinker JA, Fichman DL, Goldberg S, Holubkov R, et al. One-year follow-up of the stent restenosis (STRESS I) study. Am J Cardiol. 1998;81:860–5.PubMedCrossRef George CL, Baim DS, Brinker JA, Fichman DL, Goldberg S, Holubkov R, et al. One-year follow-up of the stent restenosis (STRESS I) study. Am J Cardiol. 1998;81:860–5.PubMedCrossRef
4.
go back to reference Savage MP, Fischman DL, Rake R, Leon MB, Schatz RA, Penn I, et al. Efficacy of coronary stenting versus angioplasty on small coronary arteries. J Am Coll Cardiol. 1998;31:307–11.PubMedCrossRef Savage MP, Fischman DL, Rake R, Leon MB, Schatz RA, Penn I, et al. Efficacy of coronary stenting versus angioplasty on small coronary arteries. J Am Coll Cardiol. 1998;31:307–11.PubMedCrossRef
5.
go back to reference Wahlau K, He Q, Ding ZP, Johan A. Safety and efficacy of angiography-guided stent placement in small native coronary artries of <3.0 mm in diameter. Clin Cardiol. 1997;20:711–6.CrossRef Wahlau K, He Q, Ding ZP, Johan A. Safety and efficacy of angiography-guided stent placement in small native coronary artries of <3.0 mm in diameter. Clin Cardiol. 1997;20:711–6.CrossRef
6.
go back to reference Horita Y, Kanaya H, Uno Y, Yamazaki T, Kaku B, Funada A. The study of intimal hyperplasia vs. reference diameter in Multi-Link Plus coronary stent: Late loss is not influenced by the reference diameter. Jpn J Interv Cardiol. 2003;18:457–62. (Japanese). Horita Y, Kanaya H, Uno Y, Yamazaki T, Kaku B, Funada A. The study of intimal hyperplasia vs. reference diameter in Multi-Link Plus coronary stent: Late loss is not influenced by the reference diameter. Jpn J Interv Cardiol. 2003;18:457–62. (Japanese).
7.
go back to reference Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF, et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with Sirolimus-eluting stents. Circulation. 2005;111:2326–9.PubMedCrossRef Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF, et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with Sirolimus-eluting stents. Circulation. 2005;111:2326–9.PubMedCrossRef
8.
go back to reference Lemons PA, Hoye A, Goedhart D, Arampatzis AC, Saia F, Giessen WJ, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after Sirolimus-eluting stent implantation in complex patients. An evaluation from Rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) study. Circulation. 2004;109:1366–70.CrossRef Lemons PA, Hoye A, Goedhart D, Arampatzis AC, Saia F, Giessen WJ, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after Sirolimus-eluting stent implantation in complex patients. An evaluation from Rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) study. Circulation. 2004;109:1366–70.CrossRef
9.
go back to reference Onuma Y, Kukreja N, Piazza N, Eindhoven J, Girasis C, Echenkeveld L, et al. The Everolimus-eluting stent in real world patients. 6-month follow-up of the X-SEARCH (Xience-V stent evaluated at Rotterdam Cardiac Hopsital) Registry. JAm Coll Cardiol. 2009;54:269–76.CrossRef Onuma Y, Kukreja N, Piazza N, Eindhoven J, Girasis C, Echenkeveld L, et al. The Everolimus-eluting stent in real world patients. 6-month follow-up of the X-SEARCH (Xience-V stent evaluated at Rotterdam Cardiac Hopsital) Registry. JAm Coll Cardiol. 2009;54:269–76.CrossRef
10.
go back to reference Valgimigli M, Meighem CAG, Ong ATL, Aoki J, Granillo GR, McFadden EP, et al. Short- and long term clinical outcomes after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease. Insight from the Rapamycin-eluting and Taxus stent evaluated at Rotterdam Cardiology Hospital Registries (RESEARCH and T-RESEARCH). Circulation. 2005;111:1383–9.PubMedCrossRef Valgimigli M, Meighem CAG, Ong ATL, Aoki J, Granillo GR, McFadden EP, et al. Short- and long term clinical outcomes after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease. Insight from the Rapamycin-eluting and Taxus stent evaluated at Rotterdam Cardiology Hospital Registries (RESEARCH and T-RESEARCH). Circulation. 2005;111:1383–9.PubMedCrossRef
11.
go back to reference Park SJ, Kim YH, Lee BK, Lee SW, Lee CW, Hong MK, et al. Sirolumus-eluting stent implantation for unprotected left main coronary artery stenosis. J Am Coll Cardiol. 2005;45:351–6.PubMedCrossRef Park SJ, Kim YH, Lee BK, Lee SW, Lee CW, Hong MK, et al. Sirolumus-eluting stent implantation for unprotected left main coronary artery stenosis. J Am Coll Cardiol. 2005;45:351–6.PubMedCrossRef
12.
go back to reference Kim YH, Park DW, Lee SW, Yun SC, Lee CW, Hong MK, et al. Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents. Circulation. 2009;120:400–7.PubMedCrossRef Kim YH, Park DW, Lee SW, Yun SC, Lee CW, Hong MK, et al. Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents. Circulation. 2009;120:400–7.PubMedCrossRef
13.
go back to reference Moses JW, Leon MB, Pompa JJ, Fitzgerald PJ, Holmes DR, O’shaughnessy C, Caputo R, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–23.PubMedCrossRef Moses JW, Leon MB, Pompa JJ, Fitzgerald PJ, Holmes DR, O’shaughnessy C, Caputo R, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–23.PubMedCrossRef
14.
go back to reference Lemos PA, Serruys PW, Domberg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization of Sirolimus-eluting stents compared with conventional bare metal stent implantation in the “Real World”. The rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry. Circulation. 2004;109:190–5.PubMedCrossRef Lemos PA, Serruys PW, Domberg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization of Sirolimus-eluting stents compared with conventional bare metal stent implantation in the “Real World”. The rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry. Circulation. 2004;109:190–5.PubMedCrossRef
15.
go back to reference Violini R, Musto C, Felice F, Nazzaro MS, Cifarelli A, Petitti T, et al. Maintenance of long-term clinical benefit with Sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2010;55:810–4.PubMedCrossRef Violini R, Musto C, Felice F, Nazzaro MS, Cifarelli A, Petitti T, et al. Maintenance of long-term clinical benefit with Sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2010;55:810–4.PubMedCrossRef
16.
go back to reference Weisz G, Leon MB, Holmes DR, Kereiakes DJ, Pompa JJ, Teirstein PS, et al. Five-year follow-up after Sirolimus-eluting stent implantation. J Am Coll Cardiol. 2009;53:1488–97.PubMedCrossRef Weisz G, Leon MB, Holmes DR, Kereiakes DJ, Pompa JJ, Teirstein PS, et al. Five-year follow-up after Sirolimus-eluting stent implantation. J Am Coll Cardiol. 2009;53:1488–97.PubMedCrossRef
17.
go back to reference Tongi M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S, et al. Impact of vessel size on outcome after implantation of Sirolimus-eluting and Paclitaxel-eluting stents. J Am Coll Cardiol. 2007;50:1123–31.CrossRef Tongi M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S, et al. Impact of vessel size on outcome after implantation of Sirolimus-eluting and Paclitaxel-eluting stents. J Am Coll Cardiol. 2007;50:1123–31.CrossRef
18.
go back to reference Mehilli J, Kastrati A, Pache J, Dirschinger J, Schoming A, for the intracoronary drug-eluting stenting to abrogate restenosis in small arteries (ISAR-SMART 3) study investigators. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Euro Heart J. 2006;27:260–6.CrossRef Mehilli J, Kastrati A, Pache J, Dirschinger J, Schoming A, for the intracoronary drug-eluting stenting to abrogate restenosis in small arteries (ISAR-SMART 3) study investigators. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Euro Heart J. 2006;27:260–6.CrossRef
19.
go back to reference Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, et al. Predictive factors of restenosis after coronary implantation of Sirolumus- or Paclitaxel-eluting stents. Circulation. 2006;113:2293–300.PubMedCrossRef Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, et al. Predictive factors of restenosis after coronary implantation of Sirolumus- or Paclitaxel-eluting stents. Circulation. 2006;113:2293–300.PubMedCrossRef
20.
go back to reference Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, et al. Intracoronary stenting and angiographic results: Struts thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001;103:2816–21.PubMed Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, et al. Intracoronary stenting and angiographic results: Struts thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001;103:2816–21.PubMed
21.
go back to reference Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter JO, et al. Intracoronary stenting and angiographic results: Struts thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283–8.PubMedCrossRef Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter JO, et al. Intracoronary stenting and angiographic results: Struts thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283–8.PubMedCrossRef
22.
go back to reference Nakagawa Y, Kimura T, Morimoto T, Nomura M, Saku K, Haruta S, et al. Incidence and risk factors of late target lesion revascularization after Sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). Am J Cardiol. 2010;106:329–36.PubMedCrossRef Nakagawa Y, Kimura T, Morimoto T, Nomura M, Saku K, Haruta S, et al. Incidence and risk factors of late target lesion revascularization after Sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). Am J Cardiol. 2010;106:329–36.PubMedCrossRef
23.
go back to reference Leon MB, Mauri L, Pompa J, Cutlip DE, Nikolsky E, O’Shaughnessy C, et al. A randomized comparison of the Endeavor Zotarolimus-eluting stent versus the Taxus Paclitaxel-eluting stent in de novo native coronary lesions. 12-month outcome from the ENDEAVOR IV trial. J Am Coll Cardiol. 2010;55:543–54.PubMedCrossRef Leon MB, Mauri L, Pompa J, Cutlip DE, Nikolsky E, O’Shaughnessy C, et al. A randomized comparison of the Endeavor Zotarolimus-eluting stent versus the Taxus Paclitaxel-eluting stent in de novo native coronary lesions. 12-month outcome from the ENDEAVOR IV trial. J Am Coll Cardiol. 2010;55:543–54.PubMedCrossRef
24.
go back to reference Stone GW, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663–74.PubMedCrossRef Stone GW, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663–74.PubMedCrossRef
25.
go back to reference Serruys PW, Silber S, Garg S, Geuns RJ, Richardt G, Buszman PE, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136–46.PubMedCrossRef Serruys PW, Silber S, Garg S, Geuns RJ, Richardt G, Buszman PE, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136–46.PubMedCrossRef
26.
go back to reference Feres F, Costa R, Abizaid A. Very late thrombosis after drug-eluting stent. Catheter Cardiovasc Interv. 2006;68:83–8.PubMedCrossRef Feres F, Costa R, Abizaid A. Very late thrombosis after drug-eluting stent. Catheter Cardiovasc Interv. 2006;68:83–8.PubMedCrossRef
27.
go back to reference Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120:391–9.PubMedCrossRef Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120:391–9.PubMedCrossRef
28.
go back to reference Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426–34.PubMedCrossRef Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426–34.PubMedCrossRef
29.
go back to reference Kim YS, Koo BK, Seo JB, Park KW, Suh JW, Lee HY, et al. The incidence and predictors of postprocedual incomplete stent apposition after angiographically success drug-eluting stent implantation. Catheter Cardiovasc Interv. 2009;74:58–63.PubMedCrossRef Kim YS, Koo BK, Seo JB, Park KW, Suh JW, Lee HY, et al. The incidence and predictors of postprocedual incomplete stent apposition after angiographically success drug-eluting stent implantation. Catheter Cardiovasc Interv. 2009;74:58–63.PubMedCrossRef
Metadata
Title
Which DES is the most appropriate for very small target vessels? Experimental study of stent expandable performance with SES, PES, ZES and EES
Authors
Yuki Horita
Masanobu Namura
Masatoshi Ikeda
Taketoshi Tsuchiya
Hidenobu Terai
Ryota Fukuoka
Naoto Tama
Toshimitsu Takagi
Publication date
01-05-2011
Publisher
Springer Japan
Published in
Cardiovascular Intervention and Therapeutics / Issue 2/2011
Print ISSN: 1868-4300
Electronic ISSN: 1868-4297
DOI
https://doi.org/10.1007/s12928-011-0053-4

Other articles of this Issue 2/2011

Cardiovascular Intervention and Therapeutics 2/2011 Go to the issue